Bloomberg Podcast: Omicron Continues To Spread

Dec 02, 2021 Hosts Alix Steel and Guy Johnson speak with Opinion Columnist Marcus Ashworth, BI Director of research Sam Fazeli, European Oil Team Leader James Herron, Certara CEO William Feehery, Grab Co-Founder Hooi Ling Tan

Certara’s Simcyp™ COVID-19 Vaccine Model Wins R&D 100 Award

Biosimulation tool to conduct ‘what-if’ scenarios with virtual patients recognized in Software/Services category PRINCETON, NJ – October 25, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that its Simcyp COVID-19 Vaccine Model has won an R&D 100 Award, which recognizes the top 100 “R&D pioneers and their revolutionary ideas in … Continued

How COVID-19 has fundamentally changed clinical research in global health

By: Jay J HParkMSc, RobinMoggPhD, Gerald ESmithMSc, EtheldredaNakimuli-MpunguPhD, FyezahJehanMBBS, Craig RRaynerPharmD, JeanineCondoPhD, Eric HDecloedtPhD, ProfJean BNachegaPhD, GilmarReisPhD, ProfEdward, JMillsFRCP COVID-19 has had negative repercussions on the entire global population. Despite there being a common goal that should have unified resources and efforts, there have been an overwhelmingly large number of clinical trials that have been … Continued

The Landscape of Emerging Randomized Clinical Trial Evidence for COVID-19 Disease Stages: A Systematic Review of Global Trial Registries

Alison Dillman,1 Michael J Zoratti,2 Jay JH Park,3 Grace Hsu,2 Louis Dron,2 Gerald Smith,2 Ofir Harari,2 Craig R Rayner,4 Noor-E Zannat,2 Alind Gupta,2 Eric Mackay,5 Paul Arora,6 Zelyn Lee,7 Edward J Mills2 A multitude of randomized controlled trials (RCTs) have emerged in response to the novel coronavirus disease (COVID-19) pandemic. Understanding the distribution of trials among various settings is important to guide future research priorities and efforts. The … Continued

How COVID-19 Affects Stakeholder Engagement & Value Communication

By Tom Hemy The COVID-19 pandemic has made the development and commercialization of pharmaceuticals and medical devices even more challenging. For example, in the value communication and stakeholder engagement area, many field representatives found themselves refused entry to hospitals and surgeries and unable to meet in-person with payers, doctors, and other key stakeholders. These meetings … Continued

1 of 3
Back to top
Powered by Translations.com GlobalLink OneLink Software